Navigation Links
Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
Date:7/11/2012

SAN DIEGO, July 11, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced an update to the projected timeframe for completion of enrollment of the Light Study, the Contrave® cardiovascular outcomes clinical trial. Orexigen now expects to complete enrollment of patients required for the interim analysis of the Light Study in the first quarter of 2013, potentially reducing by half the original projections.

"2012 has been a year of focused execution at Orexigen in order to conduct the Light Study as quickly as possible," said Michael Narachi, CEO of Orexigen. "The outstanding efforts of our team and our partners have resulted in enrollment rates of the targeted population that are much faster than originally expected."

The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events (MACE) during randomized treatment for Contrave compared to placebo. After approximately 87 MACE have been adjudicated, Orexigen will conduct an interim analysis. Orexigen plans to resubmit the Contrave New Drug Application for approval if in the interim analysis the company is able to exclude a doubling of risk of MACE in patients receiving Contrave compared to placebo.

Orexigen is targeting to enroll a patient population with a 1.5% annualized background rate of MACE. The demographics (age, gender, smoking status, prevalence of cardiovascular disease, diabetes and other co-morbidities) of the patients enrolled into the study to date are in line with the targeted population and the projected MACE rate.

Since initiation of the Light Study at the beginning of June, over 1,500 patients have been enrolled into the study at approximately 100 sites that have been activated thus far. The remaining 200 sites are scheduled to be activated by the end of August. With the revised enrollment projections, and assumin
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
4. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
5. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
6. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
7. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
8. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
9. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
10. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
11. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... MEETING, Pa., Nov. 8, 2010 Keeping radiation ... hospitals, particularly in computed tomography (CT), which has undergone some ... side is that CT delivers some of the highest radiation ... measures for delivering the appropriate radiation dose can result in ...
... Biotechnologies Corporation, a leader in the emerging field of ... financial support for the company,s lead oncology product, Rexin-G, ... Services (HHS), and the National Institutes of Health (NIH) ... latest support for the clinical advancement of Rexin-G comes ...
Cached Medicine Technology:ECRI Institute Service to Address CT Radiation Dose Safety 2ECRI Institute Service to Address CT Radiation Dose Safety 3Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy 2
(Date:4/24/2014)... virus caused the first flu pandemic in the 21st ... killed more than 50 people in the country. Since ... epidemics (winter/spring seasons). , Infections with influenza pH1N1 ... Health Organization has recommended Tamiflu for treatment of patients ... drug is that it targets viral proteins which mutate ...
(Date:4/23/2014)... unrelated donors was safe and effective in treating ... Clostridium difficile , according to a new pilot ... and available online. Known as fecal microbiota transplantation, ... a colonoscope or a nasogastric tube. The findings ... more readily available to patients. , A growing ...
(Date:4/23/2014)... SPOKANE, Wash.Researchers at Washington State University Spokane have ... are about to nod off behind the wheel. ... steering wheel movementswhich are more variable in drowsy ... to currently available video-based driver drowsiness detection systems. ... detect when a car is drifting out of ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... identified an important enzyme pathway that helps prevent new ... a condition that has been directly linked to cancer ... biochemistry, found that near the end of cell division, ... any breaks in DNA are fully repaired before the ... cells. This process helps safeguard against some of the ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... A ... by alcohol, according to Washington, D.C., personal injury attorney Mike Abelson. , ... Washington, D.C. (PRWEB) July 4, 2010 -- There ... Mike Abelson says. But on the holiday day designated to celebrate the freedoms ...
... ... Software, Today Announced That It Has Been Selected As A 2010 Emerging Technology Vendor By ... Philadelphia, PA ... software, today announced that it has been selected as a 2010 Emerging Technology Vendor by ...
... ... loss camp in the country, points out how how fantasy and reality don,t always mesh in ... new show "Huge". , ... (PRWEB) July 4, 2010 -- If it weren,t for a bit of fantasy, our lives would ...
... ... esteemed psychiatrist Dr. Lyubov Gorelik into the pages thier exclusive medical directory, The Leading ... a leader in psychiatry, and will be featured alongside other top physicians from around ... ...
... Reporter , THURSDAY, July 1 (HealthDay News) -- Complications ... can shorten the lives of patients by an average ... already shown that post-stroke complications increase mortality as well ... associate professor in the department of neurology at Ilsan ...
... ... Oxford House , ... 3, 2010 -- “Oxford House is a true blessing for those who really want recovery.” This ... Today, author Joe Chavez shares their stories in I Second The Motion: Learning to Live Sober, ...
Cached Medicine News:Health News:Don't Drink and Drive on Fourth of July Weekend, Washington, D.C., Attorney Warns 2Health News:Neuxpower Selected as 2010 Emerging Technology Vendor by CRN Magazine 2Health News:Real Life "Fat Camp" Owner Disagrees With How Such Camps Are Depicted In ABC Family's new show, "Huge" 2Health News:Real Life "Fat Camp" Owner Disagrees With How Such Camps Are Depicted In ABC Family's new show, "Huge" 3Health News:Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World 2Health News:Complications Shorten Stroke Patients' Lives 2Health News:Complications Shorten Stroke Patients' Lives 3Health News:Oxford House: Where Stories of Recovery Are Born 2
FM Style Neonatal Flowmeters (Brass Body)...
... features for the professional ophthalmic photographer. Integrated ... and background illumination, all controlled through a ... joystick, as well as adaptors allowing for ... range professional level digital and 35 mm ...
... The system that makes it all ... Biology Workstation is an automated multi-purpose ... sequences, such as in the analysis ... Short Tandem Repeats (STRs) using the ...
Assess serum Gc-globulin levels in patients with multiple trauma, fulminant liver failure, acetaminophen overdose, and sepsis....
Medicine Products: